
News|Articles|September 1, 2005
FDA actions in brief
Valsartan (Diovan, Novartis) received an expanded indication for reducing cardiovascular mortality in patients who are at high risk due to left ventricular failure or dysfunction after myocardial infarction.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
AI in Ophthalmology: The Key to the Present Success Includes a CPT Code. The Future? Agentic AI That Doesn’t Wait To Be Told What To Do | AAO 2025
2
AI and Ophthalmology: A Nearly Picture Perfect Kinda Match | AAO 2025
3
El Niño and La Niña Affect Eye Health Too, Not Just Weather | AAO 2025
4
What’s New in the Diagnosis and Treatment of Headaches That Ophthalmologists Should Know About? | AAO 2025
5